MGRX — MANGOCEUTICALS, INC.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1938046 ·
Last close
$0.55
Market Cap
$9.41M
52W High
$0.55
52W Low
$0.16
ADV30
754,259
Next earnings
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 67,864 29,001 -3,126,326 -3,403,150 14,449,223 174,562 974,571
Dec 2025 94,360 47,475 -1,490,378 -2,769,567 16,089,573 1,486,338 890,568
Sep 2025 84,246 50,899 -7,542,926 -7,618,218 16,531,802 481,281 804,275
Jun 2025 168,109 89,948 -5,268,495 -5,415,818 20,842,828 101,019 1,600,945

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,850,255
Investing CF
$0
Financing CF
$7,270,855
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.69
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-40,647,480
Inventory
$0
Receivables
$20,056
ST Investments
EBIT TTM
$-20,539,942
Pretax Income TTM
$-20,643,455
Interest Exp TTM
$-333,385
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$414,579
EBITDA
$-15,949,484
Free Cash Flow
$1,429,201
Enterprise Value
$7,860,533
Total Cash
$174,562
Total Debt
$294,023
Shares Out
17,167,422
Trailing EPS
$-1.24
Book Value
$0.96
ROE
-113.9%
ROA
-60.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 456,021 -19,154,988 -20,642,994 16,089,573 890,568 -5,850,255
Dec 2024 615,873 -8,693,526 -8,706,145 15,370,511 1,425,463 -4,863,776
Dec 2023 731,493 -9,218,890 -9,212,417 1,050,793 276,039 -6,997,375
Dec 2022 8,939 -1,991,582 -1,998,055 1,003,287 389,257 -1,346,518

Peers — same industry

TickerNameMarket CapLastDaily %
AMS AMERICAN SHARED HOSPITAL SERVICES $8.94M $1.35
MRAI Marpai, Inc. $10.88M $0.43
BMGL Basel Medical Group Ltd $10.89M $0.58
VSEE VSEE HEALTH, INC. $8.12M $0.17
ACON Aclarion, Inc. $7.78M $3.16

News headlines (Yahoo Finance, 1h cache)

BC-Most Active Stocks
2026-03-23 14:30 · Yahoo
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
2026-03-17 20:00 · Yahoo
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
2026-03-06 21:00 · Yahoo
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
2026-02-23 21:05 · Yahoo
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
2026-02-19 21:05 · Yahoo
Top Midday Decliners
2025-12-19 18:46 · Yahoo
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
2025-12-19 15:38 · Yahoo
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
2025-12-18 13:30 · Yahoo
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
2025-11-14 13:00 · Yahoo
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
2025-11-14 00:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.